APOE and Alzheimer disease: APOE4 status should be accepted as a crucial parameter in clinical trial design, patient retrieval, and data evaluation, with AD risk across age, sex, race, and ethnicity (stronger risk for East Asians vs. Hispanics) for establishing personalized AD therapy [25].